The War on Peptides, Explained by Someone in the Trenches
Brigham Buhler runs Ways2Well and co-founded ReviveRx, a compounding pharmacy. He is not a neutral observer in the peptide regulation debate. He is directly affected by it. And that is exactly why this conversation with Joe Rogan matters. You are hearing from someone who watches the regulatory sausage get made and can tell you what it smells like up close.
This episode, recorded in early 2024, landed at a time when the FDA was actively cracking down on compounding pharmacies producing peptides like BPC-157. Buhler walks through what happened, why it happened, and who benefits from restricting access to these compounds.
How Peptides Went From Available to Banned
The timeline Buhler lays out is straightforward. For years, compounding pharmacies could legally produce peptides like BPC-157, Thymosin Beta-4, and various growth hormone secretagogues under the guidance of prescribing physicians. Patients could get pharmaceutical-grade products with known purity and dosing. The system was not perfect, but it worked.
Then the FDA began reclassifying certain peptides, effectively removing them from the list of substances that compounding pharmacies could produce. Buhler's argument is that this reclassification was not driven by safety concerns. BPC-157 has a remarkably clean safety profile in the published literature. No deaths. No serious adverse events in the animal data. Decades of research without red flags.
So if it was not safety, what was it?
Follow the Money
Buhler makes the case that pharmaceutical companies have a financial interest in eliminating compounded peptides from the market. If you can get BPC-157 from a compounding pharmacy for a fraction of what a branded pharmaceutical product would cost, that is competition. And big pharmaceutical companies do not like competition.
He describes the lobbying infrastructure that exists to influence FDA decisions, the revolving door between pharmaceutical companies and regulatory agencies, and the pattern of compounds getting restricted right around the time pharmaceutical companies file patents for similar molecules. You can agree or disagree with his interpretation of motive, but the timeline he describes is documented.
Rogan, predictably, runs with this angle. The conversation gets heated at points, and Buhler's frustration is genuine. He has watched physicians lose the ability to prescribe therapies that their patients were benefiting from, and he lays the blame squarely at the intersection of pharmaceutical lobbying and regulatory capture.
BPC-157 Safety Data: What We Actually Have
One of the most useful parts of this episode is Buhler's summary of BPC-157's safety record. He walks through the published literature and points out that across hundreds of animal studies spanning decades, the adverse event profile is essentially blank. No organ toxicity. No carcinogenicity signals. No reproductive toxicity in the available data.
He contrasts this with approved pharmaceuticals that have well-documented side effect profiles and still receive FDA approval. The inconsistency, he argues, reveals that the regulatory process is not purely about safety. It is about market control.
The Compounding Pharmacy Ecosystem
Buhler explains how compounding pharmacies work, and this is valuable context for anyone unfamiliar with the space. Compounding pharmacies operate under state pharmacy boards and can produce custom medications that are not commercially available, or that need specific formulations for individual patients. They are not unregulated. They are regulated differently than large pharmaceutical manufacturers.
The nuance matters because critics of compounding pharmacies often paint them as unregulated Wild West operations. Some are better than others, certainly. But Buhler pushes back on the idea that the entire compounding industry is a quality problem. Many compounding pharmacies test their products rigorously and operate under strict quality standards.
The Specific Peptides Under Threat
Buhler names the peptides that matter most in this conversation. BPC-157 is the headliner, a body protection compound originally derived from human gastric juice that has shown tissue-healing effects across tendons, ligaments, gut lining, and brain tissue in animal studies. TB-500 (Thymosin Beta-4) is another, used primarily for wound healing and reducing inflammation. Then there are the growth hormone secretagogues, particularly CJC-1295 (with or without DAC) and Ipamorelin, which stimulate natural growth hormone release and are used for recovery, sleep quality, and body composition.
Each of these peptides was available through compounding pharmacies with a prescription. Patients could get products that were tested for purity and potency, dosed accurately, and administered under physician guidance. The FDA's reclassification disrupted that system. Buhler's frustration centers on the fact that these compounds were pulled not because patients were getting hurt, but because they competed with far more expensive branded drugs in development.
What Ways2Well Actually Does
Buhler is more than a podcast guest with opinions. He co-founded ReviveRx, a compounding pharmacy, and runs Ways2Well, a telemedicine and wellness clinic network that connects patients with physicians who prescribe peptide therapy, hormone optimization, and metabolic health protocols. The model is telehealth-first: patients get bloodwork done locally, consult with a physician remotely, and receive compounded medications shipped to their door.
This matters because it explains Buhler's proximity to the regulatory fight. When the FDA tightens rules on compounding, his businesses feel it directly. His patients lose access to therapies they were benefiting from. His pharmacists cannot produce products they have been making safely for years. That is why he speaks with the urgency he does on Rogan. You can factor that bias into your evaluation, but you should also recognize that he is describing real consequences for real patients, not hypothetical scenarios.
What Buhler Gets Right and Where to Apply Skepticism
Buhler's core factual claims hold up well. The FDA did reclassify certain peptides. Compounding pharmacies did lose the ability to produce compounds they had been making for years. The safety data on BPC-157 is genuinely clean across hundreds of studies. And the timing of pharmaceutical company patent filings relative to regulatory restrictions is a matter of public record. These are verifiable facts, not opinion.
Where healthy skepticism is warranted is on the question of motive. Buhler presents a straightforward narrative: Big Pharma lobbied the FDA to restrict peptides to eliminate competition. That is a plausible explanation, and it fits the pattern of pharmaceutical industry behavior in other markets. But regulatory decisions usually have multiple contributing factors. The FDA's stated concerns about quality control at some compounding pharmacies were not entirely invented. There were legitimate instances of contaminated or mislabeled products from less reputable compounders. Buhler tends to downplay these cases because they undermine his broader argument, and that is a gap you should keep in mind.
The strongest version of his argument is not that all compounding pharmacies are perfect, but that blanket restrictions punish good operators for the sins of bad ones. That is a reasonable position. It is different from saying the FDA had zero legitimate concerns, and Buhler sometimes blurs that line in the heat of the conversation.
If You Were Using Compounded Peptides and Lost Access
This episode aired at a time when many patients were suddenly cut off from peptides they had been using, sometimes for years, under physician supervision. If that describes you, here are practical steps based on what Buhler discusses and what the broader regulatory situation allows.
First, talk to your prescribing physician before taking any action. Some compounding pharmacies found compliant pathways to continue producing certain peptides. Your doctor may be able to switch you to a different pharmacy that still carries what you need. Second, do not panic-buy from unverified online sources. The quality risks Buhler describes are real. Products from overseas sellers or research chemical companies lack the testing and sterility guarantees that come with a licensed compounding pharmacy. You could end up injecting something contaminated or incorrectly dosed.
Third, ask your physician about alternative compounds that achieve similar goals through different pathways. If you were using BPC-157 for gut health, for example, there may be other interventions (dietary changes, specific probiotics, or different peptides still available) that your doctor can recommend as a bridge. Fourth, stay informed about regulatory changes. The situation is not static. The Buhler follow-up episodes on JRE (episodes 2376 and 2469, both covered in the FormBlends library) track how the regulatory picture evolved over the following two years, and there has been meaningful movement toward restoring some compounding access.
The Dosing and Administration Details Buhler Mentions
While most of this episode focuses on the political and economic dimensions, Buhler does drop some practical clinical details that matter. He mentions that his clinic typically prescribes BPC-157 at doses ranging from 250 to 500 micrograms per day, administered subcutaneously. For TB-500, typical protocols run 2 to 5 milligrams per week, often front-loaded in the first few weeks and then reduced to a maintenance dose. Growth hormone secretagogues like CJC-1295/Ipamorelin are usually dosed before bed to align with the body's natural nighttime growth hormone pulse.
These are not prescriptions. They are reference points for understanding what clinical use looks like compared to the often random dosing you see discussed on Reddit or bodybuilding forums. The difference between clinical peptide use and self-experimentation is physician oversight, bloodwork monitoring, and dose adjustments based on individual response. Buhler makes this point repeatedly: the compounds are not the problem, and unsupervised use by people who skip the medical infrastructure is where real risks emerge.
How This Episode Launched the Peptide Mainstream Conversation
It is easy to forget that before this 2024 JRE episode, peptides were mostly discussed in niche biohacking communities, bodybuilding forums, and longevity-focused podcasts. Buhler's appearance brought the topic to an audience of millions who had never heard of BPC-157 or understood why compounding pharmacies matter. The view count on this episode (73K at the time, which has since grown) does not capture its true reach. Clips circulated on social media. Other podcasters started covering peptides. Physicians who had been quietly prescribing peptide therapy suddenly had patients coming in with informed questions.
The two follow-up Buhler episodes on JRE built on this foundation, with audiences growing to 700K and then 364K respectively. That trajectory shows something real: public interest in peptide access did not peak and fade. It grew. And Buhler's willingness to name names, cite specific regulatory actions, and explain the economics gave people a framework for understanding the issue that most health content does not provide.
What This Means for You
If you have been using peptides or considering them, this episode gives you the political and economic context that most health content ignores. The availability of peptides in the US is not purely a science question. It is a regulatory question shaped by economic interests. Understanding that context helps you make better decisions about sourcing, timing, and alternatives.
Buhler is obviously biased. He runs businesses that are directly affected by these regulations. But biased does not mean wrong, and the facts he presents are checkable. Whether his interpretation of FDA motive is accurate is a separate question from whether the regulatory changes he describes actually happened. They did.